About Chembond Biosciences
Chembond Biosciences is a publicly listed company based in India founded in 1975. Animal feed supplements, nutrition products, and biosecurity solutions for poultry and dairy in India. It operates in the Agriculture and Chemicals & Materials sectors. The company has 1 employees. Its Indian entity Chembond Chemicals Limited reported revenue of ₹330 Cr. Chembond Biosciences offers products and services including Feed Supplements and Probiotics and Enzymes. Its focus areas include Food and Agriculture, Animal Nutrition, Feed Additives and Industrial Supplies.
Company details
Chembond Biosciences is known for delivering meticulously formulated feed and nutrition products that foster the growth and well-being of dairy and poultry animals, with an emphasis on safety and sustainability. These offerings, which include vitamins, minerals, probiotics, enzymes, and feed additives, are designed to enhance immune function, digestive efficiency, and overall vitality using advancements in science and technology. The company also provides biosecurity practices and tailored solutions to minimize disease risks and improve animal productivity, ensuring high-quality outcomes in animal health sectors.
- Headquarters India
- Employees 1
- Stage Public
- SectorsAgricultureChemicals & Materials
- Email••••••••
- Phone•••• ••••
- Social LinkedIn Facebook YouTube
- Legal Name Chembond Chemicals Limited
- Date of Incorporation 12 Dec, 2023
- Jurisdiction Thane, Maharashtra, India
- Market Cap₹604 Cr
CHEMBONDCH · NSE
- Share Price₹228.71
+1.84% today
- Revenue₹326 Cr
FY 2025-26 · +11.6% YoY
- EBITDA₹47.49 Cr
Margin 14.6%
- Net Profit₹33.83 Cr
FY 2025-26 · +12.2% YoY
- P/E (TTM)16.4x
P/B 3.0x
- ROE18.2%
ROCE 23.9%
- Employee Count1
Associated legal entities of Chembond Biosciences
Chembond Biosciences is associated with 2 registered companies on The Company Check; the primary company is Chembond Chemicals Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Chembond Chemicals Limited Listed CIN L20116MH2023PLC415282 | Active | 12 Dec 2023 | Thane, Maharashtra | ₹330 Cr | 8 | View details | |
| Chembond Chemicals Limited CIN U20116MH2023PLC415282 | 12 Dec 2023 | Thane, Maharashtra, India | View details |
Products & Services of Chembond Biosciences
Chembond Biosciences offers a comprehensive portfolio of products and services, including Feed Supplements and Probiotics and Enzymes.
Feed supplements for poultry and dairy are provided to enhance growth and well-being through balanced nutrients and additives.
Probiotics and enzymes are supplied to improve gut flora and feed digestion, thereby supporting animal immunity and productivity.
Apps and channels of Chembond Biosciences
its YouTube channel Chembond Biosciences Limited has 215 subscribers and 14 videos.
Videos from Chembond Biosciences
The most watched videos on Chembond Biosciences's YouTube channel, Chembond Biosciences Limited (215 subscribers). Click a video to play it here.
More on Chembond Biosciences Limited.
Board of directors of Chembond Chemicals Limited (Chembond Biosciences)
Chembond Chemicals Limited is the primary company behind Chembond Biosciences. The board of Chembond Chemicals Limited currently have 6 directors; the longest-serving is Sameer Vinod Shah, appointed in 2023. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sameer Vinod Shah DIN 00105721 | Director | 12 Dec 2023 | 2 yrs 10 mo | Chembond Chemicals Limited |
| Nirmal Vinod Shah DIN 00083853 | Managing Director | 12 Dec 2023 | 2 yrs 10 mo | Chembond Chemicals Limited |
| Anuradha Paraskar Shirish DIN 02331564 | Director | 01 Apr 2025 | 1 yr 6 mo | Chembond Chemicals Limited |
| Anniruddha Bhalchandra Pandit DIN 02471158 | Director | 01 Apr 2025 | 1 yr 6 mo | Chembond Chemicals Limited |
| Mahendra Kalyanji Ghelani DIN 01108297 | Director | 06 May 2025 | 1 yr 5 mo | Chembond Chemicals Limited |
| Sushil Uttamchand Lakhani DIN 01578957 | Director | 06 May 2025 | 1 yr 5 mo | Chembond Chemicals Limited |
IPO & Listings of Chembond Biosciences
Chembond Biosciences is a publicly listed company on the NSE with ticker symbol CHEMBONDCH in India, operating in the Chemicals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: CHEMBONDCH
- Listed entityChembond Chemicals Limited
- Exchange sectorChemicals
Financials of Chembond Biosciences
Exchange-reported figures of Chembond Chemicals Limited, the listed company behind Chembond Biosciences (NSE: CHEMBONDCH).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 326 | 292 | 283 | 440 | 349 |
| Revenue growth | +11.6% | +3.2% | -35.7% | +26.2% | - |
| EBITDA | 47.49 | 41.99 | 42.03 | 34.58 | 17.09 |
| EBITDA margin | +14.6% | +14.4% | +14.8% | +7.9% | +4.9% |
| Profit before tax | 45.27 | 42.16 | 42.45 | 33.67 | 20.53 |
| Net profit | 33.83 | 30.16 | 29.67 | 24.71 | 13.91 |
| Net profit margin | +10.4% | +10.3% | +10.5% | +5.6% | +4.0% |
| EPS (₹) | 13.00 | 11.54 | 11.20 | 18.36 | 10.35 |
| Balance sheet | |||||
| Total assets | 210 | 176 | 145 | 331 | 308 |
| Net worth | 207 | 174 | 144 | 322 | 304 |
| Total debt | 0.00 | 0.00 | 0.00 | 7.32 | 1.51 |
| Cash & bank | 36.36 | 25.86 | 27.10 | 20.59 | 19.44 |
| Net working capital | 144 | 109 | 89.41 | 111 | 94.54 |
| Cash flow | |||||
| Cash from operations | 8.29 | 9.79 | (55.62) | 2.17 | (10.47) |
| Cash from investing | 0.76 | (8.52) | 48.39 | 0.14 | (1.87) |
| Cash from financing | (4.04) | (0.67) | 12.85 | (2.06) | (4.09) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 86.48 | 101 | 86.35 | 73.04 | 65.38 | 78.01 | 74.88 | 75.03 |
| Revenue growth (YoY) | +32.3% | +30.0% | +15.3% | -2.7% | +1.6% | - | - | - |
| Other income | 2.78 | (0.19) | 1.05 | 0.41 | 2.72 | 1.91 | 0.19 | 1.85 |
| EBITDA | 11.33 | 15.88 | 12.36 | 10.67 | 8.42 | 12.27 | 14.40 | 7.91 |
| EBITDA margin | +13.1% | +15.7% | +14.3% | +14.6% | +12.9% | +15.7% | +19.2% | +10.5% |
| Depreciation | 1.18 | 1.53 | 1.31 | 1.32 | 1.19 | 2.45 | 0.95 | 0.52 |
| Interest | 0.15 | 0.21 | 0.17 | 0.15 | 0.15 | 0.11 | 0.24 | 0.16 |
| Profit before tax | 12.78 | 13.95 | 11.93 | 9.61 | 9.80 | 11.62 | 13.40 | 9.08 |
| Tax | 3.23 | 2.33 | 2.21 | 2.42 | 3.53 | 2.92 | 3.44 | 2.19 |
| Net profit | 9.55 | 11.62 | 9.72 | 7.19 | 6.27 | 8.70 | 9.96 | 6.89 |
| EPS (₹) | 3.54 | 4.36 | 3.62 | 2.69 | 2.33 | 3.27 | 3.71 | 2.57 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 73.65 | 69.40 | 68.86 | 50.86 | 45.64 | 42.04 |
| Revenue growth | +6.1% | +0.8% | +35.4% | +11.4% | +8.6% | - |
| EBITDA | 9.60 | 6.47 | 8.62 | 1.63 | 3.55 | 3.61 |
| EBITDA margin | +13.0% | +9.3% | +12.5% | +3.2% | +7.8% | +8.6% |
| Profit before tax | 11.79 | 7.58 | 11.02 | 4.54 | 10.91 | 12.65 |
| Net profit | 9.68 | 5.52 | 7.39 | 3.94 | 8.73 | 9.71 |
| Net profit margin | +13.1% | +8.0% | +10.7% | +7.8% | +19.1% | +23.1% |
| EPS (₹) | 3.86 | 2.24 | 2.76 | 2.94 | 6.50 | 7.19 |
| Balance sheet | ||||||
| Total assets | 102 | 94.52 | 89.93 | 242 | 245 | 240 |
| Net worth | 101 | 93.64 | 89.15 | 242 | 245 | 239 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 4.11 | 1.42 | 0.98 | 8.58 | 1.34 | 1.80 |
| Net working capital | 22.80 | 19.04 | 13.85 | 39.82 | 38.21 | 33.81 |
| Cash flow | ||||||
| Cash from operations | 8.48 | 0.77 | (4.85) | 1.96 | (0.49) | 3.81 |
| Cash from investing | (2.38) | 1.32 | (7.61) | 5.40 | 2.16 | (2.92) |
| Cash from financing | (3.45) | (1.61) | 13.35 | (6.79) | (3.07) | (0.07) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.44 | 21.90 | 18.76 | 14.49 | 18.50 | 20.46 | 18.78 | 13.58 |
| Revenue growth (YoY) | -0.3% | +7.0% | -0.1% | +6.7% | +11.6% | - | - | - |
| Other income | 1.03 | 0.44 | 0.31 | 3.03 | 0.73 | 0.42 | 0.18 | 2.46 |
| Total expenses | 15.45 | 17.81 | 16.12 | 13.97 | 16.14 | 17.60 | 15.81 | 14.56 |
| EBITDA | 2.99 | 4.09 | 2.64 | 0.52 | 2.36 | 2.86 | 2.97 | (0.98) |
| EBITDA margin | +16.2% | +18.7% | +14.1% | +3.6% | +12.8% | +14.0% | +15.8% | -7.2% |
| Depreciation | 0.64 | 0.67 | 0.50 | 0.55 | 0.51 | 0.66 | 0.65 | 0.56 |
| Interest | 0.01 | 0.07 | 0.00 | 0.00 | 0.01 | 0.06 | 0.02 | 0.02 |
| Profit before tax | 3.37 | 3.79 | 2.45 | 3.00 | 2.57 | 2.56 | 2.48 | 0.90 |
| Tax | 0.67 | (0.38) | 0.19 | 0.15 | 1.45 | 0.49 | 0.96 | (0.47) |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 86.48 | 101 | 86.35 | 73.04 | 65.38 | 78.01 | 74.88 | 75.03 |
| Revenue growth (YoY) | +32.3% | +30.0% | +15.3% | -2.7% | +1.6% | - | - | - |
| Other income | 2.78 | (0.19) | 1.05 | 0.41 | 2.72 | 1.91 | 0.19 | 1.85 |
| EBITDA | 11.33 | 15.88 | 12.36 | 10.67 | 8.42 | 12.27 | 14.40 | 7.91 |
| EBITDA margin | +13.1% | +15.7% | +14.3% | +14.6% | +12.9% | +15.7% | +19.2% | +10.5% |
| Depreciation | 1.18 | 1.53 | 1.31 | 1.32 | 1.19 | 2.45 | 0.95 | 0.52 |
| Interest | 0.15 | 0.21 | 0.17 | 0.15 | 0.15 | 0.11 | 0.24 | 0.16 |
| Profit before tax | 12.78 | 13.95 | 11.93 | 9.61 | 9.80 | 11.62 | 13.40 | 9.08 |
| Tax | 3.23 | 2.33 | 2.21 | 2.42 | 3.53 | 2.92 | 3.44 | 2.19 |
| Net profit | 9.55 | 11.62 | 9.72 | 7.19 | 6.27 | 8.70 | 9.96 | 6.89 |
| EPS (₹) | 3.54 | 4.36 | 3.62 | 2.69 | 2.33 | 3.27 | 3.71 | 2.57 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Revenue | 326 | 292 | 283 | 440 | 349 |
| Revenue growth | +11.6% | +3.2% | -35.7% | +26.2% | - |
| Other income | 3.96 | 5.83 | 3.71 | 4.64 | 8.61 |
| Total expenses | 279 | 250 | 241 | 406 | 332 |
| Employee cost | 59.72 | 49.99 | 45.39 | 67.34 | 59.98 |
| EBITDA | 47.49 | 41.99 | 42.03 | 34.58 | 17.09 |
| EBITDA margin | +14.6% | +14.4% | +14.8% | +7.9% | +4.9% |
| Depreciation | 5.35 | 4.93 | 2.61 | 4.51 | 4.48 |
| Interest | 0.83 | 0.73 | 0.68 | 1.04 | 0.69 |
| Profit before tax | 45.27 | 42.16 | 42.45 | 33.67 | 20.53 |
| Tax | 10.48 | 11.25 | 12.43 | 8.89 | 6.56 |
| Net profit | 33.83 | 30.16 | 29.67 | 24.71 | 13.91 |
| Net profit margin | +10.4% | +10.3% | +10.5% | +5.6% | +4.0% |
| EPS (₹) | 13.00 | 11.54 | 11.20 | 18.36 | 10.35 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 13.45 | 13.45 | 13.45 | 6.72 | 6.72 |
| Reserves & surplus | 194 | 161 | 130 | 315 | 297 |
| Shareholders' funds (net worth) | 207 | 174 | 144 | 322 | 304 |
| Minority interest | 0.44 | 0.61 | 0.73 | 1.39 | 1.32 |
| Secured loans | 0.00 | 0.00 | 0.00 | 6.53 | 0.80 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.79 | 0.71 |
| Total debt | 0.00 | 0.00 | 0.00 | 7.32 | 1.51 |
| Total liabilities | 210 | 176 | 145 | 331 | 308 |
| Assets | |||||
| Gross block | 47.34 | 41.42 | 37.16 | 140 | 143 |
| Net block | 22.74 | 21.08 | 21.77 | 117 | 121 |
| Capital work in progress | 0.04 | 0.30 | 0.17 | 12.37 | 0.70 |
| Investments | 30.50 | 35.46 | 27.33 | 65.10 | 75.44 |
| Inventories | 23.45 | 18.26 | 17.34 | 34.21 | 33.93 |
| Sundry debtors | 114 | 100 | 77.19 | 115 | 89.63 |
| Cash & bank balances | 36.36 | 25.86 | 27.10 | 20.59 | 19.44 |
| Loans & advances | 11.81 | 2.96 | 2.91 | 11.62 | 4.73 |
| Total current assets | 186 | 147 | 125 | 182 | 148 |
| Total current liabilities | 42.41 | 38.04 | 35.13 | 70.42 | 53.19 |
| Net working capital | 144 | 109 | 89.41 | 111 | 94.54 |
| Total assets | 210 | 176 | 145 | 331 | 308 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Opening cash | 7.10 | 6.51 | 0.89 | 8.98 | 25.41 |
| Net cash from operating activities | 8.29 | 9.79 | (55.62) | 2.17 | (10.47) |
| Net cash from investing activities | 0.76 | (8.52) | 48.39 | 0.14 | (1.87) |
| Net cash from financing activities | (4.04) | (0.67) | 12.85 | (2.06) | (4.09) |
| Net change in cash | 5.00 | 0.60 | 5.62 | 0.25 | (16.43) |
| Closing cash | 36.36 | 25.86 | 27.10 | 20.59 | 19.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +11.6% | +3.2% | -35.7% | +26.2% | - |
| EBITDA growth | +13.1% | -0.1% | +21.5% | +102.3% | - |
| PBT growth | +7.4% | -0.7% | +26.1% | +64.0% | +9997.0% |
| Net income growth | +12.2% | +1.7% | +20.1% | +77.6% | - |
| Revenue CAGR (3Y) | -9.5% | -5.7% | - | - | - |
| EBITDA CAGR (3Y) | +11.2% | +34.9% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +10.7% | +10.6% | +10.6% | +5.6% | +4.0% |
| Return on capital employed | +24.0% | +26.8% | +18.2% | +10.9% | +6.9% |
| Return on net worth | +18.3% | +19.5% | +12.9% | +7.9% | +4.6% |
| Debt / equity | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.97 | 1.97 | 1.73 | 3.46 | 5.47 |
| Efficiency & per share | |||||
| Fixed asset turnover | 7.35 | 7.44 | 3.21 | 3.12 | 2.45 |
| Inventory turnover | 15.64 | 16.42 | 10.99 | 12.93 | 10.29 |
| Debtors turnover | 3.04 | 3.29 | 2.94 | 4.30 | 3.89 |
| EPS (₹) | 13.00 | 11.54 | 11.20 | 18.36 | 10.35 |
| Dividend per share (₹) | 1.25 | 1.25 | 0.00 | 3.00 | 5.00 |
| Book value per share (₹) | 76.96 | 64.77 | 53.35 | 239.34 | 226.02 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.44 | 21.90 | 18.76 | 14.49 | 18.50 | 20.46 | 18.78 | 13.58 |
| Revenue growth (YoY) | -0.3% | +7.0% | -0.1% | +6.7% | +11.6% | - | - | - |
| Other income | 1.03 | 0.44 | 0.31 | 3.03 | 0.73 | 0.42 | 0.18 | 2.46 |
| Total expenses | 15.45 | 17.81 | 16.12 | 13.97 | 16.14 | 17.60 | 15.81 | 14.56 |
| EBITDA | 2.99 | 4.09 | 2.64 | 0.52 | 2.36 | 2.86 | 2.97 | (0.98) |
| EBITDA margin | +16.2% | +18.7% | +14.1% | +3.6% | +12.8% | +14.0% | +15.8% | -7.2% |
| Depreciation | 0.64 | 0.67 | 0.50 | 0.55 | 0.51 | 0.66 | 0.65 | 0.56 |
| Interest | 0.01 | 0.07 | 0.00 | 0.00 | 0.01 | 0.06 | 0.02 | 0.02 |
| Profit before tax | 3.37 | 3.79 | 2.45 | 3.00 | 2.57 | 2.56 | 2.48 | 0.90 |
| Tax | 0.67 | (0.38) | 0.19 | 0.15 | 1.45 | 0.49 | 0.96 | (0.47) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 73.65 | 69.40 | 68.86 | 50.86 | 45.64 | 42.04 |
| Revenue growth | +6.1% | +0.8% | +35.4% | +11.4% | +8.6% | - |
| Other income | 4.50 | 3.81 | 3.77 | 5.41 | 10.11 | 11.91 |
| Total expenses | 64.05 | 62.93 | 60.24 | 49.23 | 42.09 | 38.43 |
| Employee cost | 11.05 | 11.11 | 9.38 | 7.07 | 5.78 | 5.04 |
| EBITDA | 9.60 | 6.47 | 8.62 | 1.63 | 3.55 | 3.61 |
| EBITDA margin | +13.0% | +9.3% | +12.5% | +3.2% | +7.8% | +8.6% |
| Depreciation | 2.22 | 2.59 | 1.27 | 2.44 | 2.70 | 2.80 |
| Interest | 0.09 | 0.11 | 0.10 | 0.06 | 0.05 | 0.07 |
| Profit before tax | 11.79 | 7.58 | 11.02 | 4.54 | 10.91 | 12.65 |
| Tax | 1.40 | 1.56 | 3.57 | 0.60 | 2.19 | 2.98 |
| Net profit | 9.68 | 5.52 | 7.39 | 3.94 | 8.73 | 9.71 |
| Net profit margin | +13.1% | +8.0% | +10.7% | +7.8% | +19.1% | +23.1% |
| EPS (₹) | 3.86 | 2.24 | 2.76 | 2.94 | 6.50 | 7.19 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 13.45 | 13.45 | 13.45 | 6.72 | 6.72 | 6.72 |
| Reserves & surplus | 87.37 | 80.19 | 75.70 | 235 | 238 | 233 |
| Shareholders' funds (net worth) | 101 | 93.64 | 89.15 | 242 | 245 | 239 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 102 | 94.52 | 89.93 | 242 | 245 | 240 |
| Assets | ||||||
| Gross block | 31.79 | 27.70 | 27.44 | 42.87 | 45.71 | 44.69 |
| Net block | 17.77 | 14.80 | 17.13 | 28.50 | 32.13 | 33.72 |
| Capital work in progress | 0.03 | 0.30 | 0.17 | 7.03 | 0.40 | 0.43 |
| Investments | 62.30 | 62.08 | 60.77 | 163 | 172 | 169 |
| Inventories | 6.03 | 5.21 | 4.81 | 3.01 | 2.84 | 3.96 |
| Sundry debtors | 20.06 | 20.22 | 15.25 | 23.11 | 21.39 | 18.41 |
| Cash & bank balances | 4.11 | 1.42 | 0.98 | 8.58 | 1.34 | 1.80 |
| Loans & advances | 2.85 | 0.88 | 1.02 | 16.05 | 21.28 | 19.63 |
| Total current assets | 33.05 | 27.73 | 22.06 | 50.75 | 46.85 | 43.80 |
| Total current liabilities | 10.25 | 8.69 | 8.21 | 10.93 | 8.64 | 9.99 |
| Net working capital | 22.80 | 19.04 | 13.85 | 39.82 | 38.21 | 33.81 |
| Total assets | 102 | 94.52 | 89.93 | 242 | 245 | 240 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 1.37 | 0.89 | 0.00 | 0.40 | 1.80 | 0.99 |
| Net cash from operating activities | 8.48 | 0.77 | (4.85) | 1.96 | (0.49) | 3.81 |
| Net cash from investing activities | (2.38) | 1.32 | (7.61) | 5.40 | 2.16 | (2.92) |
| Net cash from financing activities | (3.45) | (1.61) | 13.35 | (6.79) | (3.07) | (0.07) |
| Net change in cash | 2.65 | 0.48 | 0.89 | 0.57 | (1.41) | 0.82 |
| Closing cash | 4.11 | 1.42 | 0.98 | 8.58 | 1.34 | 1.80 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +6.1% | +0.8% | +35.4% | +11.4% | +8.6% | - |
| EBITDA growth | +48.4% | -24.9% | +428.8% | -54.1% | -1.7% | - |
| PBT growth | +55.5% | -31.2% | +142.7% | -58.4% | -13.8% | +9997.0% |
| Net income growth | +75.4% | -25.3% | +87.6% | -54.9% | -10.1% | - |
| Revenue CAGR (3Y) | +13.1% | +15.0% | +17.9% | - | - | - |
| EBITDA CAGR (3Y) | +80.6% | +22.2% | +33.7% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +14.1% | +8.7% | +10.8% | +7.8% | +19.1% | +23.0% |
| Return on capital employed | +12.1% | +8.4% | +6.7% | +1.9% | +4.5% | +5.3% |
| Return on net worth | +10.7% | +6.6% | +4.5% | +1.6% | +3.6% | +4.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.22 | 2.84 | 1.36 | -7.41 | 5.88 | 8.64 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 2.48 | 2.52 | 1.96 | 1.15 | 1.01 | 0.94 |
| Inventory turnover | 13.10 | 13.85 | 17.61 | 17.39 | 13.42 | 10.62 |
| Debtors turnover | 3.66 | 3.91 | 3.59 | 2.29 | 2.29 | 2.28 |
| EPS (₹) | 3.86 | 2.24 | 2.76 | 2.94 | 6.50 | 7.19 |
| Dividend per share (₹) | 1.25 | 1.25 | 0.00 | 3.00 | 5.00 | 5.00 |
| Book value per share (₹) | 37.48 | 34.82 | 33.15 | 179.80 | 182.19 | 177.94 |
Top companies in Animal Feed & Nutrition
3 companies that operate in the same segment as Chembond Biosciences (Animal Feed & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Procures and distributes milk and dairy products through unions and online orders. | 1984 | Bengaluru, Karnataka, India | USD 2.58 M | |||
A brand specializing in high-quality milk and food products. | 2007 | Lucknow, Uttar Pradesh, India | USD 184.73 M | 1,016 | ||
Provides healthy snack options including potato chips, multigrain chips, and noodles for consumers. | 2016 | Kolkata, West Bengal, India | USD 51.28 M | 388 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Chembond Biosciences
Chembond Biosciences was founded in 1975.
Chembond Biosciences is headquartered in India.
Chembond Biosciences has 1 employees.
The primary company behind Chembond Biosciences, Chembond Chemicals Limited, reported revenue of ₹330 Cr for FY 2026, up 12% year on year.
Chembond Biosciences is known for delivering meticulously formulated feed and nutrition products that foster the growth and well-being of dairy and poultry animals, with an emphasis on safety and sustainability. These offerings, which include vitamins, minerals, probiotics, enzymes, and feed additives, are designed to enhance immune function, digestive efficiency, and overall vitality using advancements in science and technology. The company also provides biosecurity practices and tailored solutions to minimize disease risks and improve animal productivity, ensuring high-quality outcomes in animal health sectors.
Chembond Biosciences offers Feed Supplements and Probiotics and Enzymes.
Yes, Chembond Biosciences is publicly traded on NSE under the ticker symbol CHEMBONDCH.
Chembond Biosciences operates through Chembond Chemicals Limited.
The legal entities of Chembond Biosciences currently have 8 directors, including Mahendra Kalyanji Ghelani, Sushil Uttamchand Lakhani, Kiran Subhash Mukadam and others.